Q1 2026 Cipla Ltd Earnings Call Transcript
Key Points
- Cipla Ltd (BOM:500087) reported a steady revenue of INR6,957 crores with an EBITDA margin of 25.6%, reflecting strong financial performance.
- The company achieved a significant milestone by breaching the INR3,000 crore revenue threshold in India for the first time in any quarter.
- Cipla's consumer health business showed strong growth, with products like Nicotex, Omnigel, and Cipladine securing number one positions in their segments.
- In North America, Cipla maintained a leading position in the Albuterol MDI market with a 19.5% market share, demonstrating its strength in respiratory care.
- The company expanded its portfolio with key launches in complex generics and oncology, and signed an agreement to launch its first biosimilar in the US, marking a significant entry into a high-potential segment.
- Cipla faced price erosion in one of its large products in the US, impacting revenue despite achieving the highest ever US generics revenue in the prior year.
- The branded prescription business in India experienced slower growth due to modest market growth in respiratory and anti-infective therapies.
- The company's US business is adjusting to price erosion in older products, which could affect future revenue.
- Cipla's trade generics business, while showing growth, is facing increased competition, which may impact future growth rates.
- The company is dealing with ongoing geopolitical headwinds that could affect its market performance in certain regions.
Ladies and gentleman, Q1 FY '26 earnings update conference call. From supply management, we have with us today Mr Umang Vohra, Global MD and CEO; Mr. Achin Gupta, Global COO; Mr. Ashish Adukia, Global CFO, Diksha Maheshwari, Head Investor Relations. (Operator Instructions)
Please note that this conference is being recorded. I now hand the conference over to Diksha Maheshwari , Head, Investor Relations. Thank you and over to you, Miss Maheshwari.
Thank you [Andrew]. Good afternoon and a very warm welcome to Cipla's Q1 FY '26 earnings call. I'm Diksha Maheshwari from the Investor Relations team at Cipla. Let me draw your attention to the fact that on this call our discussion will include certain forward-looking statements which are predictions, projections, or other estimates about future events.
These estimates reflect management's current expectations of the future performance of the company. Please note that these estimates involve several risks and uncertainties that could cause our actual
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
